MP73-14 PROSTATE CANCER AND ANDROGEN DEPRIVATION THERAPY-IS IT THE RIGHT MANAGEMENT?

Abstract

You have accessJournal of UrologyProstate Cancer: Advanced I1 Apr 2015MP73-14 PROSTATE CANCER AND ANDROGEN DEPRIVATION THERAPY-IS IT THE RIGHT MANAGEMENT? Sanchia Goonewardene, Debbie Sharp, and Raj Persad Sanchia GoonewardeneSanchia Goonewardene More articles by this author , Debbie SharpDebbie Sharp More articles by this author , and Raj PersadRaj Persad More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2690AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Prostate cancer is a large and important clinical challenge. By 2030, prostate cancer is estimated to be the most common cancer overall (Prostate Cancer UK, 2014). NICE guidance (2008) specifies considering intermittent therapy for men having long-term androgen deprivation therapy (ADT). We aim to review if we are compliant with this. METHODS A retrospective audit over 10 years reviewing patients' electronic records, at a large urban general practice was conducted. The following data were collected: stage and grade of prostate cancer, risk stratification and length of androgen deprivation therapy. If ADT was prescribed, case notes were examined for progression to metastases, whether intermittent therapy was offered, side effects of ADT such as fatigue, cardiac risk, sexual dysfunction, and documentation of discussions along the lines of what is written in NICE guidance to combat these risks, and requirement for conversion to ‘full’ ADT. RESULTS The practice was studied had 10,610 patients registered, of whom 47 patients were found to be on ADT. Four cases were low risk disease (PSA <10, Gleason score 6, T2b or less on MRI and clinical examination). 16 cases were intermediate risk (PSA 10-20, Gleason score 7, T2c on MRI / clinical examination), the rest were high risk disease (PSA 20 or greater, Gleason score 8, T3a or above). The average length of time on ADT was 7 years. Continuous ADT was given in all cases. There were no patients who had been noted to progress to metastases. All PSAs on ADT therapy remained stable, with no obvious disease progression. No side effects were recorded. CONCLUSIONS This cohort again are one that could be easily targeted for intermittent ADT. Whilst ADT therapy, is currently being used, a better mode to consider would be intermittent ADT therapy. This has both a health and cost utility benefit. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e935 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Sanchia Goonewardene More articles by this author Debbie Sharp More articles by this author Raj Persad More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...